Semaglutide Withdrawal: Weight Regain Evidence

Two different withdrawal questions

STEP 1 asked what happened after a course of treatment ended. Its extension followed 327 participants from selected sites for a year after week 68. Both study medication and the structured lifestyle intervention stopped. This was an exploratory follow-up of a subset, not a new randomization between stopping and continuing treatment ^[1].

In that extension group, mean loss during treatment was 17.3 percent with semaglutide and 2.0 percent with placebo. Over the following year, participants regained 11.6 and 1.9 percentage points respectively. The semaglutide group remained an average 5.6 percent below its original weight at week 120 ^[1].

What two-thirds regained means

The widely repeated two-thirds figure describes the share of the earlier average loss that returned. It does not mean two-thirds of participants regained everything, or that every person regained precisely that fraction. A group average also leaves room for people with greater or smaller changes ^[1].

The extension group had lost more weight during treatment than the full original trial population. Its 17.3 percent figure therefore should not be substituted for the main STEP 1 estimate in a comparison with another drug. The participants and analysis set have changed ^[1].

A randomized continuation comparison

STEP 4 gives a different comparison. All 902 entrants initially received semaglutide. After 20 weeks, 803 who reached the maintenance dose were randomized to continue treatment or switch to placebo. Both groups continued lifestyle intervention during the following 48 weeks ^[2].

By randomization, mean weight loss was 10.6 percent. From that point, those continuing semaglutide lost a further 7.9 percent, while those switching to placebo gained 6.9 percent. The between-group difference was 14.8 percentage points. These changes start at week 20, not the original pretreatment weight ^[2].

Why the designs matter

STEP 4 helps distinguish medication withdrawal from the simultaneous end of structured lifestyle support in STEP 1. Regain occurred in its placebo-switch group despite continued lifestyle intervention. It does not show that lifestyle care is useless; it shows what happened under the particular support provided in this trial ^{[1, 2]}.

The run-in also selects the population. STEP 4 randomized people who reached the trial maintenance dose, rather than everyone who ever tried semaglutide. Both studies enrolled adults without diabetes. Their findings should not be treated as a precise forecast for a different product, population or interrupted prescription ^{[1, 2]}.

Benefits, tolerability and unanswered questions

Most cardiometabolic improvements in the STEP 1 extension moved back toward baseline after withdrawal. That extension did not systematically collect adverse events. STEP 4 reported gastrointestinal events in 49.1 percent continuing semaglutide versus 26.1 percent switched to placebo during the randomized phase; those rates do not include every difficulty experienced during initial treatment ^{[1, 2]}.

Neither design tested a taper against abrupt withdrawal, a reduced-dose maintenance strategy or a personalized restart plan. The evidence supports discussing long-term treatment goals and continuity with the prescriber, not deriving a stopping schedule from these averages. The semaglutide monograph covers the product and regulatory record; trial comparisons address a different question about relative treatment effects.

Elsewhere in this index